In addition to developing Restanza as a potential treatment for CAP, Advanced Life Sciences has received a $3.8 million contract from the Department of Defense, via the Defense Threat Reduction Agency (DTRA), to fund NDA-enabling studies to evaluate Restanza's efficacy against bioterror agents such as tularemia, plague and melioidosis. In June, the company announced that Restanza demonstrated a 100% survival rate against an inhaled lethal dose of anthrax following a 14-day course of treatment in a second non-human primate study. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID).
Conference Call to Discuss the Restanza CAP NDA
Advanced Life Sciences will host a conference call and live webcast at 8:30 a.m. Eastern Time on Monday, August 3, 2009 to discuss the Restanza CAP NDA. The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 866.362.4832 (domestic) or 617.597.5364 (international). The passcode for the conference call is 61915444. A replay of the conference call will be available until August 10, 2009. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 67060945. Investors are advised to dia
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2009 PR Newswire.
All rights reserved